>> WELCOME BACK TO GET HIS
HANDS ON THE 6 MILLION
AMERICANS ARE
LIVING WITH.
>> ALZHEIMER'S DEMENTIA AND
THAT NUMBER COULD RISE UP TO
NEARLY 40 THE MILLION WITHIN
THE NEXT FEW DECADES, THE
BIOTECH COMPANY AS THE ON
BELIEVES IT HAS A DRUG READY TO
HELP BABY BOOMERS IN THE EARLY
STAGES ABOUT TIME.
JOINING US NOW IS DOCTOR MARTIN
TOLER IS THE FOUNDER AND CEO OF
THE COMPANY MARKETS, GOOD HAVE
YOU WITH US HOW DOES THIS DRUG
WORK.
>> ADVANTAGE VERSUS
THE OTHER TRUCKS THAT ARE IN
THE PIPELINE IS PRIMARILY THAT
IT'S ALL TRUCK AND IT TARGETS
THE BAD AND THE UGLY.
IT CAUSES THE BRAIN DAMAGE AND
THE SYMPTOMS. AND AGAIN OUR
ADVANTAGE VERSUS THE OTHER
PROGRAMS FROM BUDGET AND THE
SITE IS THAT IT'S ALL DARK
AS US A GOOD SAFETY PROFILE IT
COULD BE US BOTH THERAPEUTIC
WELL ABOUT THAT DOCTOR TO ARE
WARY.
>> ARE YOU IN THE PIPELINE
RIGHT NOW IN THE DRUG
DEVELOPMENT.
>> CURRENT PLAYED JUST A
HANDFUL OF TRUCKS AND A
LATE-STAGE DEVELOPMENT
EVERYBODY HEARD ABOUT THE
BREAKTHROUGH FROM A BYE JAM WAS
THAT AND TO BUCKLE A KIND THAT
PROGRESS COULD BE THE FIRST ONE
TO MARKET. WERE A COUPLE YEARS
WE HOPE TO START A FATE SWEET.
NEXT YEAR
AND THEM WHAT TAKE US ABOUT 3
YEARS TO
COMPLETE IT. AND AND THE DRUG
COULD BE ON THE MARKET IN 45
YEARS IN TERMS OF THE PILL UH
HUH.
>> INGESTION DOCK OR HOW IS
THAT SAFER THAN OTHER FORMS OF
TREATMENT.
>> SO SO THE CURRENT RE THERE
ARE BASICALLY THE ALL THE FIRST
GENERATION OF TREATMENTS, AND
I'M REALLY
AT ODDS. SO EMILY IS ABOUT
PROTEIN THAT'S THE FIRST STEP
IN THE THE GENESIS OF
ALZHEIMER'S DISEASE. NO THESE
TREATMENTS ARE INJECTABLE THEY
HAVE BE CONFUSED.
THEY COST BECAUSE THEY
TARGET ALSO THE TO GOOD EMILY,
THEY CAUSE BRENDA TEAM, A MICRO
EMERGES. AND IT'S VERY
DIFFICULT TO JUST IMAGINE THAT
THEY COULD
BE US ABOUT THAT BECAUSE IT'S
INJECTABLE A SIDE EFFECT
PROFILE THAT COULDN'T BE DONE
THAT WAY WE HAVE DEVELOPING
WHAT WE CALL THE SECOND
GENERATION DRUG. BUT IT'S
SQUARELY FOCUSED AND VERY
SELECTED FOR THAT THAT I KNOW
IT IS
ABLE TO DO IT
IN HAS A BETTER A CIRCUS.
IT SIGNAL AND ALSO THE
POTENTIAL BE IS PROVIDE THAT
WAS SO YOU CAN ACTUALLY AVOID
THE ONSET OF DISEASE DOCTOR
TELL ARE GIVEN.
>> THAT
YOU ARE AS YOU SAY 4 TO 5 YEARS
AWAY FROM SEEING THIS DRUG ON
THE MARKET RIGHT NOW ARE THE
THE INDICATIONS THAT
YOU'RE SEEING. IN THE
DEVELOPMENT THAT ARE GIVING YOU
ENCOURAGING THAT THAT IS A IT
IS EFFECTIVE.
>> SO WE HAVE ABOUT 2000
PATIENTS DATA SET FOR WHICH WE
OF OUR
CLINICAL DATA AND THE ROAD FROM
THAT THEY'D US THAT WE WERE
ABLE TO UNDERSTAND THE
THE STATE OF THE DECEASED TO
INTERVENE TO PATIENT POPULATION
AND ALSO DETERMINED THE SINGLE
SO FAR
OUR STUDY WOULD BE WHAT'S
CALLED CONFIRMATORY THAT MEANS
WE THAT DATA WE ARE WE WILL
COME FROM A
PROSPECTIVE STUDY THAT'S RIGHT
NOW WHAT WE HAVE IS THE
ANALYSIS OF THE OF THE OF THE
POPULATIONS OR ARE THE PATIENTS
THAT ARE YOU KNOW HAVE NOT BEEN
DONE PERSPECTIVE, WHAT.
>> A DOCTOR VIA JEN IS
SEEKING FDA APPROVAL FOR ITS
OWN ALZHEIMER HOW EXACT LEE IS
YOUR IS IT DIFFERENT AND ARE
YOU CALM CONFIDENT THAT YOU'RE
GOING TO BE ABLE TO PROVIDE A
DIFFERENT SOLUTION AND
EFFECTIVE SOLUTION VERSUS
BIOGEN.
>> THE MAIN USE IT ALL STARTED
AT 20 YEARS, THERE'S A HOPE
THAT WE WILL A DRUG THAT
CAN ACTUALLY STOP OR SLOW THE
PROGRESSION OF THE DISEASE
THAT'S THE MAIN BREAKS AND
THERE ARE
2 DATA SETS. ONE IS FROM BIDEN
SAID AND I'M UP THE OTHER ONES
FROM THE SITE TRUCK OPEN 2,
4, 0, 1, SURE BOTH ANTIBODIES
THAT SHOWED THAT YOU CAN TARGET
AMYLOID AND
YOU CAN HAVE IMPROVEMENT IN THE
PROGRESSION OF DISEASE. NOW THE
NEXT STEP IS TO TRY TO FIND
LOOKS THAT ARE MORE SELECTIVE
FOR THE BACK BUT
EMILY BE SENT TO BODIES OF THE
PROBLEMS WITH THE ANTIBODIES
THAT HELP YOUR BRAIN
BUT RACIAL THERE LOOK FOR A
SELECT DIFFERENT IT SO THEY
HAVE SIDE OF THIS I JUST TALKED
ABOUT AND THEY HAVE TO BE
CONFUSED. SO IT'S VERY
DIFFICULT TO IMAGINE THAT YOU
WOULD USE THEM.
IT IN AGING POPULATION AT RISK
IN THE FIRST 20 YEARS OF THE
DISEASE. WE DON'T HAVE
THE SYMPTOMS. SO IF WE WANT TO
CHANGE THE EPIDEMIC OF
ALZHEIMER'S WE WILL NEED TO
INTERVENE BEFORE THE SYMPTOMS.
START AGAIN ALZHEIMER'S-LIKE
OTHER CHRONIC DISEASES LIKE
CARDIOVASCULAR DISEASE. WE
REALLY SEE THE PATIENTS WAY
BEFORE THEY. THE DAMAGE AND
THEY HAVE THE SYMPTOMS.
>> A DOCTOR I UNDERSTAND IT IS
A INCREDIBLY SIGNIFICANT
INVESTMENT TO DEVELOP AND BRING
A DRUG TO MARKET HOW MUCH MONEY
HAVE
YOU ALLOCATED IN ORDER TO BRING
THIS TO MARKET AND HOW MUCH YOU
PLAN ON CHARGING FOR THIS
ESPECIALLY AT A TIME WHEN
PRESCRIPTION DRUG PRICING IS A
UNDER SUCH SCRUTINY HERE IN THE
U S.
>> THAT'S A VERY GOOD QUESTION.
SO WE HAVE A DATA SET ITS WORSE
ABOUT A BILL HIM SO THEY'RE
TRYING TO BLOW UP AND ALSO WAS
VERY EXPENSIVE.
WE WILL NEED PROBABLY ABOUT
ADDITIONAL 5200 MILLION TO
BRING DESTRUCTIVE
THE MARKET. NOW IN TERMS OF THE
PRICING BUT AGAIN
EXCELLENT QUESTION. WE BELIEVE
THAT WE CAN BE CE A FRACTION OF
THE COST
OF THE ANTIBODIES CHART WOULD
BE CHARGED FOR ANTIBODIES
BECAUSE AGAIN WE HAVE A SAFE
WORLD FELL. THAT'S
SHE'S THERE TO PRODUCE THEM
THEM VERY DIFFICULT PROCESS TO
PRODUCE THESE ANTIBODIES AND
CAN BE A GOOD
USE PREVENTIVELY BEFORE YOU
ACTUALLY PUT THE BRAIN DAMAGE
AND AND AND ATROPHY OF THE
BRAIN AND CAUSING THE SYMPTOMS.
>> HOW WOULD YOUR PIPELINE
CHANGE HOW WOULD THAT GO TO
MARKET STRATEGY CHANGE IF
SENATOR LIZ THE WARRANT OR
SENATOR BERNIE SANDERS WERE TO
WIN ELECTION IN 2020 AND
POTENTIALLY WHEN YOUR DRUG
REACHES MARKET, A MEDICARE FOR
ALL PLAN IS IN PLACE.
>> AGAIN I MEAN THE COST OF
ALZHEIMER'S IN THE US,
IT'S ESTIMATED ALMOST HALF A
TRILLION ABOUT 2, 7 TO BELIEVE
THEM AND DIRECT AWESOME TO 58
ON TO THE BILL AND THEN AND
INDIRECT COSTS
SO THAT COSTS JUST SO ENORMOUS
THAT UH YOU KNOW ALL THOSE OLD
THE YOU KNOW COUNTRIES ACTUALLY
LOOKING FOR
WAY TOO TO STOP THIS
EPIDEMIC AND AGAIN IN OF THE
COSTS FOR TREATMENT, ESPECIALLY
PREVENTIVE TREATMENT WOULD BE A
FRACTION OF
A FEW KNOW WHAT WOULD YOU
ACTUALLY HAVE TO SPEND OF
TREATING THE PATIENTS ARE
TAKING CARE OF THEM AGAIN THE
TRAGEDY OF ALL SUMMER SAYS THAT
YOU HAVE 20 YEARS OF THAT THIS
IS BEFORE YOU DEVELOP THE
SYMPTOMS ARE YOU READY TO
INTERVENE. WHICH IS WHERE WE
WANT TO COME IN AND IT JUST WHY
AGAIN THE SECOND GENERATION OF
DRUGS HAVE TO
BE ORAL SAFE, AH JUST JUST BE
ABLE TO BE YOU KNOW IN
COUNTRIES PREVENTIVELY
HAVE AN IMPACT I SHOULD BEFORE
YOU HAVE THE SYMPTOMS BUT
AGAIN, THEN YOU REALLY CAN SAVE
ALL THE COSTS WHICH DESTROYED
THE COST TO TAKING CARE OF THE
PATIENTS WHEN THEY ARE
INSTITUTIONALIZED ONE DAY A
THAT REQUIRE ENO